Premium
SDX‐308 and SDX‐101, Non‐Steroidal Anti‐Inflammatory Drugs, as Therapeutic Candidates for Treating Hematologic Malignancies Including Myeloma
Author(s) -
Lentzsch Suzanne,
Elliott Gary,
Roodman G. David
Publication year - 2007
Publication title -
archiv der pharmazie
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.468
H-Index - 61
eISSN - 1521-4184
pISSN - 0365-6233
DOI - 10.1002/ardp.200700081
Subject(s) - etodolac , multiple myeloma , chemistry , pharmacology , osteoclast , drug , cyclooxygenase , cancer research , medicine , in vitro , enzyme , biochemistry
Non‐steroidal anti‐inflammatory drugs have been shown to inhibit carcinogenesis in colon cancer, and to induce apoptosis in a variety of tumor cell lines. Some anti‐tumor effects are thought to be related to their cyclooxygenase‐2‐inhibitory activity, but recent studies have shown that non‐steroidal anti‐inflammatory drugs exert their anti‐tumor effect via cyclooxygenase‐2‐independent mechanism. SDX‐308 (CEP‐18082) is a non‐cyclooxygenase‐2‐inhibiting indole‐pyran analog and is structurally related to SDX‐101, an R ‐enantiomer of etodolac. SDX‐308 has a potent anti‐myeloma effect and shows synergism in combination with other drugs for the treatment of chronic lymphocytic leukemia. In addition SDX‐308 inhibits osteoclast formation and activity and thereby might be an attractive drug for the treatment of diseases with increased osteoclast activity such as osteolytic lesions in multiple myeloma and metastatic carcinomas, as well as osteoporosis. This review covers future application of SDX‐308 as an anti‐myeloma drug regulating increased osteoclast activity.